Skip to main content
ZHEJIANG JINGXIN PHARMACEUTICAL Co., Ltd. logo

ZHEJIANG JINGXIN PHARMACEUTICAL Co., Ltd. — Investor Relations & Filings

Ticker · 002020 ISIN · CNE000001K73 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,340 across all filing types
Latest filing 2026-05-15 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002020

About ZHEJIANG JINGXIN PHARMACEUTICAL Co., Ltd.

https://www.jingxinpharm.com

ZHEJIANG JINGXIN PHARMACEUTICAL Co., Ltd. specializes in the research, development, manufacturing, and distribution of chemical drugs and active pharmaceutical ingredients (APIs). The company focuses on core therapeutic areas including the central nervous system (CNS), cardiovascular health, and digestive system disorders. Its product catalog features finished dosage forms such as tablets, capsules, and injections, with notable offerings in statins, antidepressants, and anti-infectives. The organization operates multiple production bases adhering to international quality standards, facilitating the supply of high-end generic medications and innovative drug candidates. By integrating R&D with large-scale production capabilities, the company serves a global client base, providing essential treatments for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
上海市锦天城关于京新药业2025年年度股东会的法律意见书
Regulatory Filings Classification · 82% confidence The document is a legal opinion letter issued by a law firm regarding the 2025 Annual General Meeting of Zhejiang Jingxin Pharmaceutical Co., Ltd. It outlines the convening procedures, attendance qualifications, agenda items, voting procedures, and vote results, and concludes on the legality of the meeting. It is not the AGM notice itself, not a proxy statement, nor the financial report of the company. Instead, it is a compliance/legal opinion filed as part of the company’s regulatory filings. Therefore, the appropriate category is Regulatory Filings (RNS).
2026-05-15 Chinese
2025年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It references auditing standards and responsibilities related to internal control over financial reporting as of December 31, 2025. The document is an audit opinion on the effectiveness of internal controls over financial reporting, issued by a registered accounting firm. It does not contain a full annual report or financial statements but is a standalone audit report focused on internal control. This matches the definition of an Audit Report / Information (AR). The document length is short but contains substantive audit opinion content, not just an announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is AR with high confidence. FY 2025
2026-04-23 Chinese
2026年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2026 年第一季度报告' which translates to '2026 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial indicators for the first quarter of 2026. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the quarter. It also mentions that the report is unaudited, which is typical for interim or quarterly reports. There is no indication that this is an announcement of a report or a certification document. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-04-23 Chinese
公司独立董事2025年度述职报告(徐攀)
Board/Management Information Classification · 95% confidence The document is an independent director's annual duty report for the year 2025 for Zhejiang Jingxin Pharmaceutical Co., Ltd. It details the director's attendance, duties, committee work, communication with auditors, and oversight activities during the year. It includes no financial statements or quarterly/annual financial data but focuses on governance and supervisory activities of the independent director. This type of document is a management or board-related report on director duties rather than a financial report or announcement. It does not fit into categories like Annual Report (10-K), Interim Report (IR), or Audit Report (AR). It is a detailed report on board/management information, specifically the independent director's annual report. Therefore, the best fitting category is Board/Management Information (MANG). The document length is 4251 characters, which is sufficient for a substantive report rather than a brief announcement. Confidence is high given the clear content and purpose of the document.
2026-04-23 Chinese
利益冲突管理制度（草案）（2026年4月制定）
Governance Information Classification · 95% confidence The document is titled '利益冲突管理制度' (Conflict of Interest Management System) and is a detailed policy document outlining the management, declaration, investigation, and prevention of conflicts of interest for the company's directors and senior management. It includes procedural rules, definitions, and forms related to conflict of interest declarations and approvals. There is no indication that this is a financial report, earnings release, or regulatory filing announcement. It is a governance-related document detailing internal rules and procedures for managing conflicts of interest within the company. Therefore, it fits best under Governance Information (CGR). The document length is 4426 characters, which is substantive and contains detailed policy content rather than a brief announcement or certification.
2026-04-23 Chinese
2025年年度报告摘要
Annual Report Classification · 100% confidence The document is titled '2025 年年度报告摘要' which translates to '2025 Annual Report Summary'. It contains detailed financial data including revenue, net profit, earnings per share, and other financial metrics for the year 2025, as well as business descriptions, product lines, market position, and strategic initiatives. The length is substantial (15,000 characters), indicating it is a full report rather than a brief announcement. The content includes comprehensive financial and operational information typical of an Annual Report. Therefore, this document fits the definition of an Annual Report (10-K). FY 2025
2026-04-23 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.